Trials / Completed
CompletedNCT04516746
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 32,450 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Accepted
Summary
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
Detailed description
The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AZD1222 | AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein. |
| BIOLOGICAL | Placebo | Commercially available 0.9% (n/V) saline for injection. |
Timeline
- Start date
- 2020-08-28
- Primary completion
- 2021-03-05
- Completion
- 2023-02-10
- First posted
- 2020-08-18
- Last updated
- 2024-02-05
- Results posted
- 2022-04-01
Locations
84 sites across 3 countries: United States, Chile, Peru
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04516746. Inclusion in this directory is not an endorsement.